Flotetuzumab: an Investigational CD123xCD3 Bispecific DART® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies is Associated with Response to Treatment in Primary Refractory AML Patients

John E. Godwin MD,1 Carmen Ballesteros-Merino PhD,1 Nikhil Lonberg BS,2 Shawn M. Jensen PhD,2 Tarsem Moudgil MS,2 Carlo B. Bifulco MD,2 Sarah E. Church PhD,2 Thomas Smith PhD,2 Michael Bailey MS,2 James Gowan-McDonald MS,2 Sergio Rutella MD PhD,3 Jon M. Wigginton MD,3 John Muth MS,3 Jan Davidson-Moncada MD PhD,3 Bernard A. Fox PhD,3


Preliminary GeoMx DSP Analysis identifies: 1) An increase in T-cell activation markers including PD-1 and PD-L2, by cells in the CD3+ clusters vs non-clustered CD3+ ROIs (P=0.0495); 2) An increase in specific CD3+ T cells and CD123+ cells, with a higher ratio of CD3+ : PD-L1+ cells in responders vs non-responders; 3) A trend toward a lower ratio of CD3+ : PD-L1+ cells in responders vs non-responders (P=0.082); 4) A trial combining flotetuzumab with sequential administration of a PD-1 inhibitor (MGA012; also known as INCmGA00012) is currently recruiting (ASH 2019 poster 2622)